Martha Stewart on the spot

Martha Stewart built a billion-dollar empire selling taste to the American public, with a TV show, a magazine, and a line of endorsed products at Kmart. But Stewart’s future—and that of her empire—is now in doubt. Why?

Why is Stewart in trouble?

On Dec. 27 of last year, Stewart suddenly sold $228,000 worth of shares in a pharmaceutical company called ImClone. The Securities and Exchange Commission believes Stewart dumped the 4,000 shares because she had inside information. ImClone, owned by a close friend, Samuel Waksal, had been awaiting FDA approval of its highly touted cancer drug, Erbitux. But on Dec. 28, the FDA announced that the research on Erbitux was flawed, and it would not permit the drug to be marketed. That sent the stock’s value into free fall.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us